SEOUL, Jan. 30 (Korea Bizwire) – Celltrion Inc., a major South Korean biopharmaceutical company, said Friday it has launched its biosimilar Avtozma for the treatment of autoimmune diseases in three European countries. The launches in Germany, Spain and France follow approvals last year from local authorities for both the intravenous (IV) and subcutaneous (SC) formulations [...]
SEOUL, Dec. 31 (Korea Bizwire) — Celltrion Inc., a major South Korean biopharmaceutical company, said Wednesday it expects its annual operating profit to exceed 1 trillion won (US$693 million) for the first time this year, driven by strong sales of high-end products. The company forecast its operating profit will more than double to 1.16 trillion [...]
SEOUL, Dec. 26 (Korea Bizwire) — South Korea’s two leading biosimilar makers, Celltrion and Samsung Bioepis, are converging in global scale but diverging sharply in how they produce and sell their medicines, according to a new industry analysis released this week. A report by Korea Ratings said the contrasting strategies have become a defining feature of [...]
SEOUL, Dec. 22 (Korea Bizwire) — Celltrion Inc., a major South Korean biopharmaceutical company, said Monday it has launched its biosimilar drug Stoboclo-Osenvelt in major European markets, following the product’s initial rollout in the United States in July. Stoboclo-Osenvelt received sales approval from the European Commission (EC) in February, becoming a biosimilar referencing U.S. biotech [...]
SEOUL, Dec. 12 (Korea Bizwire) — Celltrion Inc. said Friday that its autoimmune biosimilar Avtozma has been added to the preferred drug list of Synergie Collective, one of the five largest pharmacy benefit managers in the United States—an endorsement that could significantly widen the drug’s market access. The South Korean biopharmaceutical company said the agreement will [...]
SEOUL, Oct. 10 (Korea Bizwire) – Celltrion Inc., a leading South Korean biopharmaceutical company, said Friday its biosimilar for eye diseases has received approval for sale in the United States. The U.S. Food and Drug Administration (FDA) has approved Eydenzelt, Celltrion’s biosimilar referencing Eylea, for the treatment of wet age-related macular degeneration and other ophthalmic [...]
SEOUL, Aug. 28 (Korea Bizwire) — Celltrion Inc., a leading South Korean biopharmaceutical company, said Thursday it will strengthen its biosimilar lineup in Vietnam to meet rising demand in the Southeast Asian country. Celltrion launched two biosimilars in Vietnam this year — Remsima, for the treatment of autoimmune diseases, in June, and Herzuma, for breast [...]
SEOUL, May 21 (Korea Bizwire) — Celltrion Inc., a leading South Korean biopharmaceutical company, said Wednesday it expects limited impact from recent U.S. policy developments stemming from a drug pricing executive order signed by President Donald Trump. Last week, Trump announced an executive order introducing a most-favored nation (MFN) pricing model, intended to align U.S. [...]
SEOUL, May 15 (Korea Bizwire) — Celltrion Inc., a leading South Korean biopharmaceutical company, said Thursday its business will remain largely unaffected by U.S. President Donald Trump’s executive order aimed at lowering drug prices to match those in other countries. The order seeks to address a drug pricing system in which the United States pays [...]
SEOUL, April 14 (Korea Bizwire) — Celltrion Inc., a major South Korean biopharmaceutical firm, said Monday it has obtained an interchangeability approval for its biosimilar drug for autoimmune disease treatment in the United States. The U.S. Food and Drug Administration (FDA) designated Celltrion’s biosimilar Yuflyma as interchangeable medicine for its original drug Humira in the [...]